Introduction
Microglia have a tissue macrophage lineage and constitute the innate immune system of the central nervous system. The activities of microglia are critical for various neuronal functions, including clearance of neuronal debris, tissue repair, synaptic plasticity, and neurotrophic factor release (1,2). Microglia also release various cytokines and growth factors to facilitate repair of neurons affected by disordered CNS homeostasis. However, abnormal microglial activation is maladaptive. Many pro-neuroinflammatory cytokines and cytotoxic mediators, including interleukin (IL)-12, IL-1β, IL-6, tumor necrosis factor (TNF)-α and reactive oxygen species (ROS) are induced in response to abnormal microglial activation. This abnormal induction is injurious to neurons and results in neurodegenerative disease (3–5). The proper maintenance of microglial activation is important for brain development and brain injury repair. Several studies have characterized the neuroinflammatory response that abnormal microglial activation induces (6,7). Notably, this response promotes the development of neurodegenerative diseases, such as Huntington's, Alzheimer's and Parkinson's.
Microglia can be categorized into two types based on distinct patterns of activation: classical M1 microglia and the alternative M2 microglia. M1 microglia activate inflammatory cytokines, including inducible IL-12, IL-1β, IL-6 and TNF-α, and promote neuronal injury. In contrast, M2 microglia produce anti-inflammatory molecules that reduce inflammation and repair tissue injury (8–10). Microglia with an M2-like phenotype release anti-neuroinflammatory molecules, such as nuclear factor erythroid 2-related factor 2 (Nrf2), NADPH dehydrogenase quinone-1 (NQO-1) and heme oxygenase-1 (HO-1) (11). These multifunctional proteins are involved in neuronal defense and repair systems. Nrf2 is a transcription factor that is responsible for the activation of several phase II antioxidant enzymes. Under unstimulated conditions, the negative regulator Kelch-like ECH-associated protein 1 (Keap1) maintains Nrf2 in the cytoplasm, which results in its ubiquitination and proteasomal degradation. During electrophilic stress, Keap1 is altered and Nrf2 translocates to the nucleus, binds to the antioxidant response element (ARE) promotor sequence, and activates the transcription of its target genes, including HO-1 and NQO1 (12,13). Genetic and pharmacological studies indicate that both NQO1 and HO-1 provide neuroprotection. For example, cell culture studies have demonstrated that NQO1 and HO-1 overexpression in neuronal cells decreases oxidative damage following exposure to amyloid βor glutamate. Consequently, microglia from HO-1 and NQO1-overexpressing transgenic mice are more resistant to lipopolysaccharide (LPS)-mediated and oxidative injury (14).
AMP-activated protein kinase (AMPK) is a family of intracellular serine/threonine protein kinases that serve roles in context-specific metabolism in response to metabolic stress, such as oxidative stress and neuroinflammation (15). Growing evidence suggests that AMPK activation prevents neuronal oxidative stress and damage under several pathological conditions. Furthermore, recent studies have demonstrated that AMPK is a negative modulator of neuroinflammatory responses and that AMPK has anti-neuroinflammatory properties in LPS-treated microglia. Thus, AMPK activation indicates an anti-neuroinflammatory response, regulates catabolism and anabolism and improves redox balance. AMPK also promotes microglial polarization towards the M2 phenotype (16,17). Consistent with the emerging interplay between oxidative stress and neuroinflammation responses, recent studies suggest the possibility of cross talk between the AMPK and Nrf2/ARE pathways (18). A previous study from our group reported that AMPK signaling regulates microglia-induced Nrf2/ARE activation and that the AMPK inhibitor compound C suppressed neuroinflammation (19). Other studies have demonstrated that the inhibition of AMPK ameliorates the LPS-stimulated neuroinflammatory response through the inactivation of Nrf2/ARE signaling (20).
Natural compounds are gaining prominence as valuable candidate substrates for the development of medications. Bakkenolide B, the main constituent of Petasites japonicus leaves, is generally cultured in East Asia and used as both a vegetable and a folk remedy (21). P. japonicus has been used to treat various diseases, including headaches, chronic cough, fever, and asthma. A bioassay study has demonstrated that P. japonicus extracts and compounds have antioxidant, anti-inflammatory, and antitumor biological effects (22). P. japonicus bakkenolide B has been previously demonstrated by our group to exhibit both antiallergenic and anti-inflammatory effects (23). Furthermore, sesquiterpenoids from P. japonicus have neuroprotective properties in human neuroblastoma SH-SY5Y cells (24,25). However, the effects of bakkenolide B on microglia-mediated neuroinflammatory activity have not been investigated. Thus, the present study investigated the effects of bakkenolide B on the microglial neuroinflammatory response. Additional mechanistic experiments verified that AMPK was associated with Nrf2/ARE activation. Taken together, the present results indicate that bakkenolide B may a potential candidate for treatment of abnormal neuroinflammatory-mediated neurodegenerative diseases.
Materials and methods
Reagents
CM-H2DCFDA was obtained from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Compound C, dimethyl sulfoxide (DMSO), MTT and other reagents were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco (Thermo Fisher Scientific, Inc.). Antibodies for α-tubulin [cat. no. sc-23948, 1:10,000 dilution, mouse immunoglobulin (Ig)G], TATA-binding protein (TBP, cat. no. sc-204, 1:500 dilution, rabbit IgG), inducible nitric oxide synthase (iNOS, cat. no. sc-8310, 1:1,000 dilution, rabbit IgG), Nrf2 (cat. no. sc-722, 1:500 dilution, rabbit IgG), NQO1, (cat. no. sc-16464, 1:1,000 dilution, rabbit IgG) and HO-1 (cat. no. sc-10789, 1:1,000 dilution, rabbit IgG), as well as small interfering (si)RNAs against Nrf2 (cat. no. sc-37049), NQO1 (cat. no. sc-37140) and HO-1 (cat. no. sc-35555), were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Antibodies against AMPK (cat. no. 2532, 1:1,000 dilution, rabbit IgG) and phosphorylated (p-) AMPK (cat. no. 2535, 1:1,000 dilution, rabbit IgG) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). FuGENE HD transfection reagent and X-tremeGENE siRNA transfection reagent were obtained from Roche Diagnostics (Indianapolis, IN, USA). A cytotoxicity detection kit, measuring lactate dehydrogenase (LDH) activity, was purchased from Roche Diagnostics (Basel, Switzerland). A mouse Quantikine ELISA kit (for TNF-α cat. no. MTA00B; IL-1β cat. no. MLB00C; IL-6 cat. No M6000B and IL-12 cat. no. M1270) was acquired from R&D Systems, Inc. (Minneapolis, MN, USA). All other basic experimental supplies and reagents were obtained from Sigma-Aldrich (Merck KGaA) and Invitrogen (Thermo Fisher Scientific, Inc.).
Extraction, isolation, and structure elucidation of bakkenolide B
Bakkenolide B was isolated using open column chromatography and its structure was previously elucidated by NMR spectroscopy (23). Briefly, the leaves of P. japonicus (425.36 g) were ground to fine particles using an electric mixer (HMF-3100 S; Hanil Electric, Seoul, Korea) for extraction at room temperature with 75% EtOH. The EtOH was then removed with a rotary evaporator and the remaining aqueous extract was fractionated consecutively with n-hexane, EtOAc, BuOH, and water. The acquired hexane extract (2.6728 g) was evaporated in vacuum and the residue was used for silica gel (40 µm; J.T. Baker; Thermo Fisher Scientific, Inc.) column chromatography (100×4.0 cm) with a step gradient of 2.5, 15, and 25% acetone in dichloromethylene and 15 and 25% MeOH in chloroform to obtain 62 fractions. Fraction 9 (MWLSH9; 304.9 mg) was separated on a Sephadex column (100×3.0 cm) with MeOH as the eluent to obtain seven fractions. Fraction 3 (MWLSH9IC; 209.7 mg) was additionally separated on a Sephadex column (100×3.0 cm) with MeOH to obtain five fractions. Fractions 2 and 3 (MWLSH9ICIB; 202.3 mg) were passed through a silica gel column (100×4.0 cm) with 1.5% acetone in CH2Cl2 as the eluent to yield bakkenolide B (173.8 mg). Pure bakkenolide B was identified using HPLC on a Phenomenex Luna C18 column (150 4.6 mm ID; 5 µ particle size; Phenomenex, Torrance, CA, USA) with an acetonitrile-water reagent alcohol gradient at a flow rate of 1.0 ml per min. Bakkenolide B (Fig. 1A) isolated from P. japonicus leaves was identified using 1H, 13C, and distortionless enhancement based on polarization transfer nuclear magnetic resonance spectroscopy in CDCl3, in contrast to previously reported spectral data (23).
Microglia culture
Mouse BV2 microglial cells, which were a generous gift from Professor Youn-Chul Kim at Wonkwang University (Iksan, Korea), were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum at 37°C in a humidified atmosphere containing 5% CO2. All experiments were performed with cells between passages 15 and 25. Bakkenolide B was solubilized with DMSO at a final concentration of 0.1% and the stock solutions were directly added to the culture media.
Cell viability assay
The toxicity of bakkenolide B was assessed using an LDH leakage assay and an MTT reduction assay. Briefly, 5×104 cells were seeded in 24-well plates and allowed to grow to 80% confluence. MTT solution (50 µg/ml) was then added to each sample. Following incubation for 6 h, the supernatant was removed, and the formazan crystals that formed in the normal cells were dissolved in DMSO. The absorbance of each sample was then measured at 570 nm using a Victor3 plate reader (PerkinElmer, Inc., Waltham, MA, USA). Extracellular LDH activity was determined using a cytotoxicity detection kit, according to the manufacturer's protocol. The absorbance in each well was quantified at 490 nm with a Victor3 plate reader (PerkinElmer, Inc.).
Measurement of IL-1β, IL-6, IL-12 and TNF-α levels
IL-1β, IL-6, IL-12 and TNF-α levels were quantified in the culture media using an ELISA kit (TNF-α cat. no. MTA00B; IL-1β cat. no. MLB00C; IL-6 cat. No M6000B and IL-12 cat. no. M1270) R&D Systems, Inc.), according to the manufacturer's protocol.
Measurement of nitric oxide (NO) production
LPS (1 µg/ml) was added to microglia and incubated for 24 h, following which the supernatant was obtained and mixed with Griess reagent, as previously reported (26). The absorbance of each mixture was then measured at 540 nm using a Victor3 plate reader (PerkinElmer, Inc.). The concentration of NO was determined using an NO standard.
Measurement of intracellular ROS
The intracellular ROS level, as an indicator of general oxidative stress, was estimated using the CM-H2DCFDA reagent. Briefly, 4×105 cells were seeded in 6-well plates and allowed to grow to 80% confluence. The cells were then harvested and washed thrice with phosphate buffer saline (PBS). A total of 10 µM CM-H2DCFDA reagent was added to cells and incubated for 30 min in a 5% CO2 at 37°C. The fluorescence intensity was subsequently measured using a flow cytometer (Beckman Coulter, Inc., Brea, CA, USA). Finally, data were quantified using the CXP version 2.0 software (Beckman Coulter, Inc.). At least 10,000 cells were evaluated for each condition.
Gene silencing of murine Nrf2, HO-1 and NQO1
Knockdown of Nrf2, HO-1, and NQO1 using siRNA (10 nM) was achieved with the X-tremeGENE siRNA transfection reagent kit, according to the manufacturer's protocols. Further experiments were performed 24 h following transfection. Nrf2, HO-1, NQO1, or control siRNA-transfected cells were used to measure the IL-1β, IL-6, IL-12 and TNF-α levels.
Transient transfection and dual luciferase assay
Cells were transfected using the HO-1 promoter reporter plasmid or ARE reporter plasmids (100 ng; Agilent Technologies, Inc., Santa Clara, CA, USA) using FuGENE-HD reagent (Roche Applied Science, Penzberg, Germany), according to the manufacturer's protocol. A Renilla luciferase control plasmid was co-transfected as an internal control for transfection efficiency. Luciferase activity was examined using a dual-luciferase assay kit (Promega Corporation, Madison, IW, USA), according to the manufacturer's protocol. Luminescence was measured using a Victor3 plate reader (PerkinElmer, Inc.).
Western blot analysis
The cell were lysed with Radioimmunoprecipitation assay buffer(Thermo Fisher Scientific, Inc.) supplemented with a protease inhibitor cocktail. The nuclear extracts were prepared using the NE-PER nuclear and cytoplasmic extraction reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Lysate protein concentrations were evaluated using Bio-Rad Protein Assay Dye Reagent concentrate (Bio-Rad Laboratories, Hercules, CA, USA). Proteins in each sample (30–50 µg of total protein) were subjected to a 7.5–10% SDS-PAGE. and transferred to a polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% skimmed milk in PBS with 0.1% Tween-20 for 1 h at room temperature. The membrane was incubated with the primary antibodies (α-tubulin, TBP, iNOS, Nrf2, NQO1 and HO-1 at room temperature for 2 h and AMPK and p-AMPK at 4°C overnight). Subsequently, the membranes were incubated with horseadish peroxidase conjugated seceondary antibodies (goat anti-rabbit, cat. no. sc-2004, 1:1,000; goat anto-mouse cat. no. sc-2039, 1:1,000) at room temperature for 1 h. The membrane was visualized using a boosted chemiluminescent immunodetection system (Amersham; GE Healthcare, Chicago, IL, USA) and a secondary horseradish peroxidase-conjugated antibody. The data were quantified using an ImageQuant 350 analyzer (ImageQuant TL SecurITy 8.0 software, Amersham; GE Healthcare).
Statistical analysis
Each experiment was repeated at least three times. Statistical analyses were conducted using the SPSS software version 18.0 (SPSS, Inc., Chicago, IL, USA). One-way analysis of variance followed by Dunn's post-hoc test was performed to identify differences among groups. P<0.05 was considered to indicate a statistically significant difference.
Results
Bakkenolide B ameliorates neuroinflammatory cytokines in LPS-stimulated microglia
First, MTT and LDH assays were used to evaluate the viability of microglia exposed to bakkenolide B (0–100 µM). The results demonstrated that bakkenolide B treatment at concentrations of 5–40 µM did not significantly affect microglia viability (Fig. 1B and C). Thus, in subsequent experiments, the microglia were evaluated following exposure to bakkenolide B at concentrations of 5–40 µM. The anti-neuroinflammatory properties of bakkenolide B were then examined in LPS-stimulated microglia. Microglia exposed to LPS displayed increased IL-1β, IL-6, IL-12 and TNF-α production compared with control cells exposed to vehicle. Conversely, bakkenolide B pretreatment reversed the effects of LPS on IL-1β, IL-6, IL-12 and TNF-α production in a dose-dependent manner (Fig. 2A). The enzyme activity and protein expression of iNOS were also investigated, because this is known to be important for neuroinflammatory responses. Treatment with bakkenolide B significantly decreased NO production induced by LPS (Fig. 2B). In addition, pretreatment with bakkenolide B resulted in markedly decreased protein expression levels of iNOS (Fig. 2C). CM-H2DCFDA staining, which is a general oxidative stress indicator, was used to assess the impact of bakkenolide B pretreatment on LPS-stimulated microglia. The results demonstrated that LPS exposure increased ROS production to 23.5±4.3% in LPS-stimulated microglia compared to 5.8±0.1% in control untreated cells. Conversely, bakkenolide B pretreatment significantly decreased the LPS-induced ROS production (15.5±1.7%; Fig. 3). As expected, N-acetyl-L-cysteine (NAC; a ROS scavenger) significantly attenuated the LPS-induced ROS (Fig. 3). Taken together, these results suggest that bakkenolide B can inhibit the production of pro-neuroinflammatory cytokines and mediators in LPS-stimulated microglia.
Bakkenolide B activates Nrf2/ARE signaling and reduces neuroinflammation in LPS-stimulated microglia
To better understand the molecular pathway through which bakkenolide B inhibits the LPS-induced neuroinflammatory response, we evaluated whether Nrf2/ARE signaling is induced in bakkenolide B-treated microglia. First, the levels of nuclear Nrf2 accumulation activation were examined using western blotting and a luciferase promoter assay following treatment of microglia with bakkenolide B. As presented in Fig. 4A, nuclear Nrf2 accumulation rapidly increased 1 h following bakkenolide B treatment. Furthermore, bakkenolide B dose-dependently increased nuclear Nrf2 accumulation (Fig. 4A). Nuclear extracts were analyzed for the α-tubulin cytoplasmic marker and minimal cytoplasmic contamination was observed (Fig. 4A). Consistent with this result, bakkenolide B significantly induced the expression of HO-1 and NQO1 in microglia compared with controls, in a time- and dose-dependent manner (Fig. 4B). Bakkenolide B-treated microglia lysates were prepared to measure ARE promoter activity (based on luciferase activity normalized to renilla luciferase activity), and the results indicated that bakkenolide B dose-dependently increased ARE-promoter activity (Fig. 4C). Consistent with this finding, bakkenolide B also significantly increased the transcriptional activity of the HO-1 promoter in a dose-dependent manner (Fig. 4D). To test the hypothesis that the anti-neuroinflammatory properties of bakkenolide B are diminished following knockdown of Nrf2, HO-1 and NQO1, TNF-α levels were evaluated using a Quantikine ELISA kit following exposure of microglia to LPS. The results revealed that TNF-α production was markedly increased in LPS-stimulated cells transfected with the control siRNA, while exposure to bakkenolide B and the control siRNA significantly decreased TNF-α production compared with the LPS-only group (Fig. 4E). Notably, transfection of siRNA for Nrf2, HO-1 or NQO1 partially reversed the bakkenolide B-mediated inhibition of TNF-α production in LPS-stimulated microglia (Fig. 4E). These findings suggest that bakkenolide B may have significant anti-neuroinflammatory properties mediated by the Nrf2/ARE pathway.
Bakkenolide B-induced AMPK-mediated Nrf2/ARE activation is vital for the suppression of LPS-induced neuroinflammation
To determine if AMPK signaling mediates bakkenolide B-induced Nrf2/ARE activation, the AMPK activation level were determined following bakkenolide B treatment in microglia using western blotting and antibodies targeting total and phosphorylated (at Thr 172) AMPK. As expected, bakkenolide B induced AMPK phosphorylation in a time- and dose-dependent manner (Fig. 5A and B). To determine if AMPK inhibition decreases Nrf2/ARE activation, nuclear Nrf2 accumulation and protein expression of HO-1 and NQO1 were evaluated by western blot analysis. As expected, the AMPK inhibitor compound C significantly inhibited bakkenolide B-induced AMPK phosphorylation (Fig. 5C). Notably, AMPK inhibition decreased bakkenolide B-induced nuclear Nrf2 accumulation and protein expression of HO-1 and NQO1 (Fig. 5C). To confirm that AMPK-mediated Nrf2/ARE signaling regulated the anti-neuroinflammatory properties of bakkenolide B protection against LPS-induced neuroinflammation, microglia were pretreated with compound C prior to exposure to bakkenolide B. Following treatment with bakkenolide B, microglia were exposed to LPS for 24 h. As illustrated in Fig. 5D, compound C pretreatment partially reversed the bakkenolide B-mediated inhibition of TNF-α production. Taken together, these results suggest that AMPK activity is required for bakkenolide B-induced Nrf2 activation and subsequent anti-neuroinflammatory activity.
Discussion
The prevalence of neurodegenerative disorders has increased nowadays and has become one of the most serious health issues worldwide. Neurodegenerative disorders are associated with a higher risk of neurodegenerative diseases, including Huntington's, Alzheimer's and Parkinson's (27,28). Abnormal microglia activation has a crucial role in the development of neurodegenerative disorders, although the exact mechanisms have not been fully elucidated. Limiting the production of neuroinflammatory mediators is crucial for neuronal protection and repair. Abnormal activation of the microglia and upregulation of pro-neuroinflammatory mediators are pathological features of neurodegenerative disorders (29–31). Furthermore, abnormal microglial accumulation and release of neuroinflammatory mediators is deleterious to neighboring neurons and may be related to neurodegenerative disease (32). The current study presents several major findings. First, bakkenolide B was demonstrated to have the potential for use as a treatment to ameliorate abnormal neuroinflammatory responses. Second, AMPK/Nrf2/ARE signaling was demonstrated to have a significant role in the anti-neuroinflammatory activities of bakkenolide B. The present study is the first to demonstrate the anti-neuroinflammatory mechanisms that regulate the effects of bakkenolide B in LPS-stimulated microglia.
Neuronal injury results from ongoing abnormal microglia activation or deficient/suppressed neuron recovery. Abnormal microglia activation contributes to the development of neurodegenerative disorder, and recent evidence has highlighted the anti-neuroinflammatory effects in microglia, providing novel potential avenues for treatment of neurodegenerative diseases (33). These proinflammatory cytokines, including TNF-α, IL-1β, IL-6 and IL-12, are secreted from microglia and initiate, amplify, and perpetuate the neuroinflammatory response in the brain. These cytokines are the primary endogenous mediators of the neuroinflammatory reaction, causing not only abnormal microglia activation, but also triggering damage to adjacent neurons (34,35). The present study demonstrated that following LPS exposure, IL-1β, IL-6, IL-12 and TNF-α in microglia are significantly increased. However, pretreatment with bakkenolide B significantly reduced the levels of IL-1β, IL-6, IL-12 and TNF-α in microglia. ROS were also induced via inflammatory mediators during the neuroinflammatory response in microglia, but this LPS-induced production of ROS was diminished following bakkenolide B pretreatment. These results demonstrated that the anti-neuroinflammatory properties of bakkenolide B in microglia may be attributed to the inhibition of IL-1β, IL-6, IL-12 and TNF-α, and ROS production.
Nrf2/ARE signaling in microglia is essential to reducing neuronal cell death and preserving cognitive function. Studies of microglia have reported that HO-1 and NQO1 overexpression, mediated by Nrf2 activation, has a strong anti-neuroinflammatory effect (11). This finding has been observed in both cell culture and animal models treated with different natural compounds that activate Nrf2/ARE to reduce the LPS-induced pro-inflammatory response and inhibit oxidative damage. Natural compounds exhibit both antioxidant and anti-inflammatory effects depending on the Nrf2/ARE signal that prevents neurodegeneration. Several studies have reported that phase II antioxidant enzymes may contribute to neural deterioration in neurodegenerative disorders and diseases. Remarkably, Nrf-2 signaling activates phase II antioxidant enzymes, such as HO-1 and NQO-1 (12,13). These enzymes serve crucial roles in neurodegenerative disorders via abnormal neuroinflammatory responses. The present results also indicate that bakkenolide B-induced Nrf2 activation upregulated HO-1 and NOQ1 expression and consequently diminished LPS-mediated neuroinflammatory responses.
AMPK is an essential factor in the protein kinase cascade that has a vital role in regulation of energy metabolism, which is important for the regulation of cell homeostasis. A previous study has reported that the molecular mechanisms and signaling pathways regulating AMPK signal activation that mediate its neuroprotective effects are driven by its anti-neuroinflammatory activities (36). Furthermore, the neuroprotective action of AMPK may not only be mediated by its antioxidant and anti-inflammatory action, but also due to the enhancement of Nrf2/ARE signaling. Indeed, studies have demonstrated the involvement of molecules downstream of AMPK in the modulation of Nrf2 activation and HO-1 and NQO-1 expression in neurons and microglia (18,19). More recently, the role of AMPK in the induction of neuroprotective factors has been confirmed in mice that show improved recovery following stroke in response to AMPK-dependent Nrf2/ARE signaling activation in the hippocampus (37). Thus, Nrf2/ARE activation has been demonstrated to be neuroprotective. Consistent with this finding, the present study demonstrated that the anti-neuroinflammatory properties of bakkenolide B were attributed to the activation of AMPK/Nrf2/ARE signaling. Bakkenolide B-mediated AMPK signaling was critical in Nrf2/ARE activation, which subsequently suppressed LPS-mediated neuroinflammatory responses. These results suggest that bakkenolide B may reduce LPS-stimulated neuroinflammatory responses by inducing the AMPK/Nrf2/ARE signaling pathway.
In conclusion, this is the first study linking bakkenolide B, isolated from P. japonicus, with AMPK signaling. These findings are especially important because AMPK mediates activation of Nrf2, HO-1 and NQO1. Bakkenolide B mediated the activation of AMPK, subsequently induced nuclear Nrf2 translocation, and promoted Nrf-2-mediated HO-1 and NQO1 expression, leading to attenuation of LPS-stimulated neuroinflammatory response (Fig. 6). Overall, these results suggest that bakkenolide B exposure may be a promising therapeutic strategy to protect against abnormal microglia activation in neurodegenerative diseases.